Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Thomas Gad Sells 10,810 Shares

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the completion of the sale, the insider now owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Y-mAbs Therapeutics Stock Performance

Shares of YMAB traded up $0.18 during trading hours on Tuesday, hitting $4.94. The company had a trading volume of 338,078 shares, compared to its average volume of 467,358. Y-mAbs Therapeutics, Inc. has a 52-week low of $4.25 and a 52-week high of $17.78. The firm has a fifty day moving average price of $6.22 and a 200-day moving average price of $10.38. The stock has a market capitalization of $223.38 million, a price-to-earnings ratio of -9.15 and a beta of 0.65.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its earnings results on Tuesday, March 4th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The firm had revenue of $26.50 million during the quarter, compared to the consensus estimate of $26.70 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same quarter in the prior year, the company posted ($0.02) EPS. Research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Wedbush reaffirmed an "outperform" rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a research report on Thursday, December 5th. They issued a "buy" rating and a $17.00 target price for the company. Morgan Stanley dropped their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research report on Wednesday, March 5th. HC Wainwright reissued a "buy" rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, January 13th. Finally, Bank of America dropped their target price on shares of Y-mAbs Therapeutics from $14.00 to $12.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Y-mAbs Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $19.30.

Remove Ads

Hedge Funds Weigh In On Y-mAbs Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Infinitum Asset Management LLC purchased a new position in shares of Y-mAbs Therapeutics in the fourth quarter worth $1,218,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Y-mAbs Therapeutics by 17.4% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 52,356 shares of the company's stock worth $410,000 after buying an additional 7,765 shares in the last quarter. Two Sigma Investments LP raised its position in Y-mAbs Therapeutics by 31.6% in the 4th quarter. Two Sigma Investments LP now owns 88,337 shares of the company's stock worth $692,000 after buying an additional 21,196 shares during the last quarter. Rafferty Asset Management LLC raised its position in Y-mAbs Therapeutics by 17.6% in the 4th quarter. Rafferty Asset Management LLC now owns 41,255 shares of the company's stock worth $323,000 after buying an additional 6,178 shares during the last quarter. Finally, ProShare Advisors LLC bought a new position in Y-mAbs Therapeutics during the 4th quarter valued at about $99,000. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.